Ocular Therapeutix reports Q4 and full-year 2025 results—non-GAAP EPS -$0.29 (flat YoY) and revenue $13.2M (-22% YoY), beating EPS but missing revenue estimates—updates AXPAXLI Phase 3 timelines with SOL-1 topline data due later this month, and ends the year with $737.1M cash providing runway into 2028.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.